Abiopharma

🔍 DIVITA CHARLES III (Director)

Company: Teladoc Health, Inc. (TDOC)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 39,160 shares of Common Stock (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 367,022.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 25,493 shares of Common Stock (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 392,515.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 27,731 shares of Common Stock at $5.49 per share (Direct)
  Date: 2026-03-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 364,784.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 39,160 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 195,803.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Acquired 43,703 shares of Performance Stock Units (Derivative)
  Date: 2026-03-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 43,703.00 | transaction_form_type: 4 | Footnotes: F5, F6, F7, F7
• Sold 25,493 shares of Performance Stock Units (Derivative)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,210.00 | transaction_form_type: 4 | Footnotes: F2, F8, F8

Footnotes:

• F1: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
• F2: Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
• F3: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
• F4: On June 10, 2024, the reporting person was granted 469,924 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
• F5: Each performance stock unit represents a contingent right to receive one share of TDOC common stock.
• F6: Performance award amount determined based on metrics in respect of the issuer's 2025 financial results.
• F7: The performance stock units vest as to seven-twelfths on March 10, 2026, with the remainder vesting in five substantially equal quarterly installments over the subsequent 15 months.
• F8: On March 10, 2026, the reporting person earned 43,703 performance stock units, vesting seven-twelfths on March 10, 2026, with the remainder vesting in five substantially equal quarterly installments over the subsequent 15 months.